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Abstract
Background—The non-selective opioid receptor antagonist, naltrexone (NAL), reduces alcohol 
(ethanol) consumption in animals and humans and is an approved medication for treating alcohol 
abuse disorders. Proopiomelanocortin (POMC)-derived melanocortin (MC) and opioid peptides 
are produced in the same neurons in the brain, and recent pre-clinical evidence shows that MC 
receptor (MCR) agonists reduce excessive ethanol drinking in animal models. Interestingly, there 
is a growing body of literature revealing interactions between the MC and opioid systems in the 
modulation of pain, drug tolerance, and food intake.
Method—In the present report, a mouse model of binge ethanol drinking was employed to 
determine if the MCR agonist, melanotan-II (MTII), would improve the effectiveness of NAL in 
reducing excessive binge-like ethanol drinking when these drugs were co-administered prior to 
ethanol access.
Results—Both NAL and MTII blunt binge-like ethanol drinking and associated blood ethanol 
levels, and when administered together, a low dose of MTII (0.26 mg/kg) produces a 7.6-fold 
increase in the effectiveness of NAL in reducing binge-like ethanol drinking. Using 
isobolographic analysis, it is demonstrated that MTII increases the effectiveness of NAL in a 
synergistic manner.
Conclusions—The current observations suggest that activators of MC signaling may represent a 
new approach to treating alcohol abuse disorders, and a way to potentially improve existing NAL-
based therapies.
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Alcohol abuse disorders and alcoholism are major public health problems in the United 
States and world-wide. The Center for Disease Control places alcohol as the number three 
cause of preventable deaths following nicotine use and obesity (Mokdad et al., 2004). The 
economic costs of alcohol misuse in the United States are estimated at about $225 billion per 
year (Bouchery et al., 2011). Further, alcohol dependence effects on the order of 5–6% of 
men and 2–3% of women in the United States in a given 12 month period (Grant et al., 
2004). Despite these alarming statistics, at present there are only four US Food and Drug 
Administration (FDA)-approved medications for treating alcohol abuse disorder, and these 
medications are not effective in all individuals (Garbutt, 2009). Thus, identifying additional 
pharmacotherapies, or ways to improve existing FDA-approved medications, is of 
paramount importance.
Neuropeptide systems stemming from the polypeptide precursor proopiomelanocortin 
(POMC) may be useful targets for treating alcohol (herein referred to as ethanol) abuse 
disorders. POMC gives rise to β-endorphin, an endogenous opioid peptide, and the 
melanocortin (MC) peptides including α-melanocyte stimulating hormone (α-MSH), β-
MSH, and γ-MSH. These peptides are synthesized primarily in the arcuate nucleus of the 
hypothalamus (Dores et al., 1986, Hadley and Haskell-Luevano, 1999). β-endorphin neurons 
provide projections to brain regions implicated in modulating ethanol consumption and the 
reinforcing properties of ethanol (Khachaturian et al., 1985), and there is a large database 
suggesting that β-endorphin modulates neurobiological responses to ethanol (Froehlich and 
Li, 1993, Gianoulakis, 2001, Rasmussen et al., 2002). Furthermore, non-selective opioid 
receptor antagonists as well as those selective for the μ or δ opioid receptors reduce ethanol 
consumption (Gianoulakis, 2001) and ethanol intake is reduced in μ opioid receptor 
knockout mice (Roberts et al., 2000, Hall et al., 2001). Consistent with an important role for 
opioid peptides, the non-selective opioid receptor antagonist naltrexone (NAL) is the active 
agent in two of the four currently approved medications for alcoholism in the United States. 
NAL prevents relapse to heavy drinking and can enhance abstinence in human alcoholics 
(see (Garbutt, 2010)).
More recent evidence reveals that POMC-derived MC neuropeptides also modulate 
neurobiological responses to ethanol. Ingestion of an ethanol-containing diet by rats 
significantly attenuates α-MSH levels in brain regions implicated in the reinforcing 
properties of ethanol (Navarro et al., 2008), and intraperitoneal injection of ethanol in mice 
increases brain levels of agouti-related protein (AgRP), an endogenous MC receptor (MCR) 
antagonist (Cubero et al., 2010). Further, central and peripheral administration of the MCR 
agonist melanotan-II (MTII) significantly blunts ethanol drinking, while central 
administration of the MCR antagonist AgRP significantly increases, and genetic deletion of 
AgRP significantly reduces, ethanol drinking in mice (Navarro et al., 2005, Navarro et al., 
2003, Navarro et al., 2009). Both the MC-4 receptor (MC4R) (Navarro et al., 2011) and the 
MC3R (Olney et al., 2014) modulate the effects of MTII on ethanol intake.
Interactions between the endogenous opioid and MC systems are now well documented and 
may be a consequence of these systems sharing a similar anatomical distribution in the 
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central nervous system with potentially opposing downstream actions. Administration of 
MC antagonists prevents and reverses the development of opioid tolerance (Contreras and 
Takemori, 1984, Starowicz et al., 2005, Starowicz et al., 2003). Further, stimulation of 
MCRs block, whereas MC4R antagonists enhance, the antinociceptive effects of opioids 
(Ercil et al., 2005) and MC1R knockout mice display an enhanced sensitivity to opioid 
antinociception (Mogil et al., 2005). Interestingly, chronic activation of the opioid system 
decreases MC4R mRNA (Alvaro et al., 1996). More recently, it has been shown that 
combined administration of NAL and a putative stimulator of MC signaling is a more 
effective treatment strategy against excessive eating than monotherapy with NAL alone 
(Greenway et al., 2009, Greenway et al., 2010). MCRs and opioid receptors are Gs and Gi 
protein-coupled, respectively, thus MCR agonists may exert effects on opioids by opposing 
the actions of opioids on intracellular signaling cascades in neurons that express both MC 
and opioid receptors (Alvaro et al., 1997, Contreras and Takemori, 1984).
Given the growing body of evidence suggesting interactions between POMC-derived MC 
and opioid neuropeptide pathways in pain modulation, opioid tolerance, and food intake, and 
the observations that NAL and MCR agonists reduce excessive ethanol drinking, here we 
determined if combining the MCR agonist MTII with NAL would synergistically increase 
the effectiveness of NAL to blunt binge-like ethanol drinking in mice. First, we established 
that NAL and MTII can significantly blunt binge-like ethanol drinking in mice using 
“drinking in the dark” (DID) procedures (Rhodes et al., 2005, Thiele and Navarro, 2014). 
Then, using drug combination and isobolographic analyses, we showed that a low dose of 
MTII significantly shifted the dose-response curve of NAL to the left, providing evidence 
that MTII synergistically increases the effectiveness of NAL in protecting against binge-like 
ethanol drinking. These observations suggest that using MCR agonists may be a new 
strategy for treating alcohol abuse disorders, and provide evidence that MCR agonists may 
increase the effectiveness of currently approved therapies involving NAL.
MATERIAL AND METHODS
Animals
As sex differences in MC neuroanatomy and function have already been described (Lippert 
et al., 2014, Qu et al., 2014, Gelez et al., 2010), only male C57BL/6J mice (Jackson 
Laboratories, Jackson, MS), 6–8 weeks of age and weighing between 20–25 g at the 
beginning of the experiments, were used. Mice were individually housed in plastic cages, 
were allowed to habituate to their environment for at least 1 week before the start of the 
experiments, and had ad libitum access to standard rodent (Prolab® RMH 3000, Purina 
LabDiet®, Inc., St. Louis, MO) and water except when is noted. The colony room was 
maintained at approximately 22°C with a 12h light/12h dark cycle and lights went off at 
10:00 hours. All procedures used were in accordance with the National Institute of Health 
guidelines, and were approved by the University of North Carolina Institutional Animal 
Care and Use Committee.
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Ethanol (20% v/v) solutions were prepared using tap water and 95% ethyl alcohol. The 
opioid antagonist naltrexone (naltrexone hydrochloride; Sigma-Aldrich, Saint Louis, MO) 
and the melanocortin agonist melanotan-II (MTII; Bachem, Torrance, CA) were dissolved in 
0.9% saline. MTII was chosen as this drug is peripherally bioavailable (Navarro et al., 
2003).
Blood-Ethanol Concentration (BEC)
Approximately 10μl of blood was collected from the tail vein of each mouse immediately 
following ethanol access on day 4 (test day) of the drinking in the dark (DID) procedure to 
analyze BEC. Samples were centrifuged, and 5μl of plasma from each sample was analyzed 
(Analox Instruments, Lunenburg, MA).
“Drinking in the Dark” (DID) Procedure
For all the experiments, we used a 4-day DID procedure to generate binge-like ethanol 
drinking (Thiele et al., 2014). On days 1–3, beginning 3 hours into the dark cycle, water 
bottles were removed from all cages and replaced with a pre-weighted bottle containing 20% 
(v/v) ethanol solution. Mice had 2 hours of access to ethanol, after which the ethanol bottles 
were removed from cages and weighed again to calculate ethanol consumption, and water 
bottles were replaced. On day 4, the test day, the same procedure was followed except that 
tail blood samples were collected immediately after ethanol intake in Experiments 1 and 2 
for analysis of BEC.
Experiments 1 & 2: Naltrexone and MTII Dose-Response Studies
To assess the effect of NAL on binge-like ethanol drinking and to establish effective doses 
(ED), we performed a dose-response experiment with NAL using the DID procedure. Mice 
were assigned to one of five groups (n = 9–14/group) so that average body weights were 
similar between groups: 0, 0.3, 1.0, 3.0, or 10 mg/kg NAL. On days 1–3 animals were 
weighed and injected intraperitoneally (i.p.) with the appropriate volume (5 ml/kg) of the 
vehicle to habituate them to the injections. On the test day, i.p. injections of NAL were 
given approximately 30 minutes before ethanol access. In a separate study using the same 
procedures, mice were assigned to one of five groups (n = 10–12/group) so that average 
body weights were similar between groups (0, 0.3, 1.0, 3.0, or 10 mg/kg groups) to assess 
the effect of MTII on binge-like ethanol drinking and to establish EDs.
Experiments 3 & 4: NAL-MTII Interaction Studies
The drug interaction and isobolographic analyses used in Experiments 3 and 4 required the 
calculations of EDs from dose-response functions from NAL and MTII alone, as well as 
these drugs in combination. To allow ED analyses and to facilitate comparisons across 
groups that had slightly different baseline levels of ethanol consumption, the data from these 
experiments were converted to % decrease from baseline ethanol consumption for each 
subject, where baseline consumption was calculated as the average ethanol intake over days 
1–3 of the DID procedure.
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Experiments 3 and 4 were designed to determine the way MTII and NAL interact (i.e., 
additively or synergistically) in the modulation of binge-like ethanol drinking. As 
Experiments 1 and 2 overlapped with the initiation of Experiments 3 and 4, data from a 
subset of mice from Experiments 1 and 2 were used to calculate ED20, ED30, and ED50 for 
each drug (n = 45 for NAL, n = 48 for MTII), and these values were used for analyses in 
Experiments 3 and 4. In Experiment 3, the influence of different doses of NAL (0.3, 1.0, and 
3.0 mg/kg) alone (obtained in Experiment 1) or in combination with the ED20 (0.26 mg/kg) 
or ED30 (0.52 mg/kg) doses of MTII were assessed on binge-like ethanol drinking (for a 
total 6 groups, n = 9–14/group). Similarly, in Experiment 4 the influence of different doses 
of MTII (0.3, 1.0, and 3.0 mg/kg) alone (obtained in Experiment 2) or in combination with 
the ED20 (0.82 mg/kg) or ED30 (1.64 mg/kg) doses of NAL were assessed on binge-like 
ethanol drinking (for a total 6 groups, n = 8–12/group). On days 1–3 animals were weighed 
and injected twice with the appropriate volume (5 ml/kg) of the vehicle to habituate them to 
the injections. On the test day each animal received an i.p. injection of one of the drugs 
(NAL or MTII) followed immediately by an i.p. injection of the other drug. It should be 
noted that mice in the NAL and MTII alone groups were tested at a different time and 
received one, rather than two, i.p. injection on habituation and test days (in Experiment 1). 
Despite these differences from mice run in Experiments 3 and 4, % baseline ethanol 
consumption levels were similar between the 0.3 and 1.0 mg/kg doses of NAL alone and 
groups that included MTII (see Figure 2), and between all doses of MTII alone and groups 
the included NAL (see Figure 3).
Statistical Analysis
To obtain a measure that corrected for individual differences in body weight, grams of 
ethanol consumed per kilogram of body weight were calculated. For all experiments, 
differences between groups in consumption or BECs were analyzed using analysis of 
variance (ANOVA). With significant interaction effects, or main effects in the absence of 
significant interactions, post hoc comparisons were performed using Tukey’s tests to parse 
out group differences. In all cases, p < 0.05 (two-tailed) was used to indicate statistical 
significance.
Isobolographic Analysis of Drug Interactions
The dose-addition model, which represents a widely accepted but non-mechanistic model of 
drug interactions (Tallarida, 2001, Tallarida, 2006, Loewe, 1953), was used to evaluate the 
interaction effects between MTII and NAL on binge-like ethanol drinking (Experiments 3 
and 4). The dose-additional model can be used to assess how drugs interact (additive or 
synergistic) by plotting data in an isobologram (see Fig. 4). First, dose-effect curves were 
generated from the data in Figure 1, 2 and 3 by expressing the percentage decrease in 
ethanol consumption as a function of the dose of each drug or drug combination examined. 
For NAL and MTII alone, the dose that produced a 20, 30 and 50% (i.e., ED20, ED30, ED50) 
decrease in ethanol consumption was derived by log-linear interpolation on the linear 
portion of the group dose-effect curve. For drug combinations, only the ED50 dose was 
determined.
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Next, the ED50 and 95% confidence levels (C.L). for the effects of NAL (solid circle) and 
MTII (solid square) alone on binge-like ethanol drinking were plotted along the abscissa and 
ordinate, respectively. Then the ED50 and 95% C.L. for each drug when tested in 
combination with the ED20 or ED30 of the other drug were then plotted. Graphically, the 
solid diagonal line that connects the two ED50 points of MTII and NAL alone represents the 
dose combinations that would be predicted to decrease binge-like ethanol drinking by 50% if 
the two drugs interacted in an additive manner. The area between dashed lines that connect 
the 95% C.L. of the ED50 for each drug alone represents the “area of additivity”, or the area 
in which drug interactions were considered to be additive. The region to the left of the 
dashed line defines synergistic drug interactions. When the ED50 and C.L. for a particular 
drug combination fell within the area of additivity, the drug interaction was considered 
additive. When the ED50 and C.L.s for a particular drug combination fell to the left of the 
theoretical area of additivity, the interaction was considered to be supra-additive or 
synergistic.
RESULTS
Experiment 1 & 2: NAL and MTII Dose-Response Studies
Ethanol consumption and blood ethanol concentrations (BECs) from the NAL dose-response 
study are presented in the top row of Fig. 1(A–B). One-way ANOVAs performed on ethanol 
consumption [F(4, 49) = 8.24, p < 0.001] and BEC [F(4, 49) = 5.57, p < 0.05] data both 
achieved statistical significance. Post hoc analyses revealed that the groups treated with the 
3.0 and 10.0 mg/kg doses of NAL drank significantly less ethanol and had lower BECs 
relative to the vehicle treated control group. Ethanol consumption and BECs from the MTII 
dose-response study are presented in the bottom row of Fig. 1(C–D). One-way ANOVAs 
performed on ethanol consumption [F(4, 53) = 16.04, p < 0.001] and BEC [F(4, 53) = 8.69, 
p < 0.001] data both achieved statistical significance. Post hoc analyses revealed that the 
groups treated with the 1.0, 3.0, and 10.0 mg/kg doses of MTII drank significantly less 
ethanol and had lower BECs relative to the vehicle treated control group. Based on effective 
dose (ED) ED50 values, MTII (1.92 mg/kg, 1.25 – 2.94 95% C.L.) was 4.2-fold more potent 
than NAL (8.13 mg/kg, 4.31 – 15.34 C.L.) in blunting binge-like ethanol drinking. MTII 
was also more effective, as the highest dose tested (10.0 mg/kg) produced a 72% decrease in 
ethanol consumption, whereas with NAL the maximal effect was only 47% (at the 10.0 
mg/kg dose).
Experiment 3 & 4: NAL-MTII Interaction Studies
Experiment 3—Average baseline ethanol consumption (average of days 1–3 of DID 
testing) among the groups were as follows: 0.3 mg/kg NAL (4.02 ± 0.21, 3.15 ± 0.31, & 
2.70 ± 0.32 g/kg at each dose level of MTII, respectively), 1.0 mg/kg NAL (3.70 ± 0.15, 
3.15 ± 0.22, & 2.75 ± 0.26 g/kg at each dose level of MTII, respectively), and 3.0 mg/kg 
NAL (3.29 ± 0.25, 3.15 ± 0.23, & 2.50 ± 0.34 g/kg at each dose level of MTII, respectively). 
Fig. 2 shows the effects of NAL alone, and in combination with the approximate ED20 (0.26 
mg/kg) and ED30 (0.52 mg/kg) doses of MTII, on binge-like ethanol intake. When 
administered in combination with selected doses of NAL (0.3 to 3.0 mg/kg), the ED20 dose 
of MTII produced leftward shifts in the NAL dose-effect curve. Based on the ED50 values, 
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the 0.26 mg/kg dose of MTII shifted the NAL dose-effect curve (ED50 of 1.07 mg/kg, 0.50 – 
2.27 C.L.) to the left by a factor of 7.6; that is, naltrexone was 7.6-fold more potent when 
administered in combination with MTII relative to when it was administered alone. The 
largest effect produced by this combination of NAL and MTII (68% reduction relative to 
control consumption), which was obtained at the 3.0 mg/kg dose of NAL, was considerably 
larger than that obtained when the 3.0 mg/kg dose of NAL was administered alone (30%). 
Somewhat different effects were obtained when doses of NAL were combined with the 
higher ED30 (0.52 mg/kg) dose of MTII, as each dose of NAL decreased the level of ethanol 
consumption to a similar extent, with the range across doses of 53% (0.3 mg/kg) to 67% (3.0 
mg/kg). Consequently, an ED50 value for the NAL dose-response curve, when combined 
with the ED30 dose of MTII, could not be determined (and is thus absent from the 
isobolographic analysis shown in Fig. 4 below). Further, when compared to the NAL alone 
condition, the 0.52 mg/kg dose of MTII did not further increase the ability of NAL to reduce 
binge-like ethanol drinking. A two-way, 3 × 3 (NAL dose x MTII dose) ANOVA performed 
on the data in Fig. 2 revealed a significant main effect of NAL dose [F(2, 90) = 3.46, p < 
0.05] and MTII dose [F(2, 90) = 5.64, p < 0.01], but the interaction effect did not attain 
statistical significance [F(4, 90) = 0.75, p > 0.05]. Post hoc comparisons of the MTII dose 
main effect revealed that combining the 0.26 mg/kg (ED20) dose of MTII with NAL 
increased the ability of NAL to blunt binge-like ethanol drinking relative to the NAL alone 
condition. Post hoc comparisons of the NAL dose main effect revealed no significant group 
differences.
Experiment 4—Average baseline ethanol consumption (average of days 1–3 of DID 
testing) among the groups were as follows: 0.3 mg/kg MTII (3.56 ± 0.31, 3.25 ± 0.20, & 
2.77 ± 0.33 g/kg at each dose level of NAL, respectively), 1.0 mg/kg MTII (3.39 ± 0.26, 
3.08 ± 0.23, & 2.69 ± 0.27 g/kg at each dose level of NAL, respectively), and 3.0 mg/kg 
MTII (3.52 ± 0.24, 3.71 ± 0.30, & 2.66 ± 0.25 g/kg at each dose level of NAL, respectively). 
Fig. 3 shows the effects of MTII alone, and in combination with the approximate ED20 (0.82 
mg/kg) and ED30 (1.64 mg/kg) doses of NAL, on binge-like ethanol drinking. Based on the 
ED50 values, the 0.82 mg/kg (ED50 of 1.80 mg/kg, 1.11 – 2.91 C.L.) and 1.64 mg/kg (ED50 
of 1.07 mg/kg, 0.39 – 2.93 C.L.) doses of NAL minimally shifted the MTII dose-effect 
curve (0.3 to 3.0 mg/kg) to the left by a factor of 1.08 and 1.79, respectively. The largest 
effect on binge-like ethanol drinking produced by 0.82 and 1.64 mg/kg doses of NAL (61% 
and 68% reduction of binge-like ethanol drinking relative to the control, respectively), 
which were obtained at the 3.0 mg/kg dose of MTII, were similar to that obtained when this 
dose of MTII was administered alone (61% reduction relative to the control condition). A 
two-way, 3 × 3 (MTII dose x NAL dose) ANOVA performed on the data in Fig. 3 revealed 
a significant main effect of MTII dose [F(2, 81) = 18.58, p < 0.001], but the NAL dose [F(2, 
81) = 1.16, p > 0.05], and the interaction effect [F(4, 81) = 0.41, p > 0.05] did not achieve 
statistical significance. Post hoc comparisons of the MTII dose-response factor revealed that 
each of the MTII doses differed from each other, reflecting the dose-dependent blunting of 
binge-like ethanol drinking by MTII.
Isobolographic Analysis of Drug Interactions—Fig. 4 shows the isobolographic 
analysis of the effects of NAL and MTII administered in selected combinations. The low 
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ED20 dose of MTII (0.26 mg/kg) synergistically augmented the ability of NAL to blunt 
binge-like ethanol drinking, shifting the ED50 value of NAL to the left beyond the area of 
additivity and into the region representing synergistic drug interactions. Although 
administering 0.52 (ED30) mg/kg of MTII in combination with selected doses of NAL 
decreased ethanol consumption in a dose-dependent manner, as noted above calculations of 
the ED50 values (and 95% C.L.) could not be obtained as all doses of MTII produced 
comparable decreases in ethanol consumption. Also evident in Fig. 4 is that neither the low 
ED20 (0.82 mg/kg) nor moderate ED30 (1.64 mg/kg) doses of NAL synergistically altered 
the ED50 values for MTII-induced blunting of binge-like ethanol drinking, as the ED50 for 
these drug dose combinations fell within the area of additivity, though the ED30 dose of 
NAL moved the ED50 for MTII to the borderline between additive and synergistic 
interactions. Taken together, these data show that a low dose of MTII synergistically 
augments the ability of NAL to blunt binge-like ethanol drinking.
Discussion
The outcomes from the experiments described herein are as follows: 1) In mice exhibiting 
binge-like levels of ethanol intake (i.e., consumption that led to BECs greater than 100 
mg/dL under control conditions), both NAL and MTII significantly reduced binge-like 
ethanol drinking in a dose-dependent manner. As noted above, MTII was 4.2-fold more 
potent than NAL, and was more effective at reducing binge-like drinking. 2) When 
administered together, a low dose (0.26 mg/kg) of MTII increased the effectiveness of NAL 
to blunt binge-like ethanol drinking in mice. Based on the ED50 values, the 0.26 mg/kg dose 
of MTII shifted the NAL dose-effect curve to the left by a factor of 7.6, indicating that NAL 
was 7.6-fold more potent when administered in combination with MTII relative to when it 
was administered alone. Interestingly, a moderate dose of MTII (0.52 mg/kg) failed to 
increase the effectiveness of NAL in reducing binge-like ethanol drinking. 3) On the other 
hand, 0.82 and 1.64 mg/kg doses of NAL failed to alter the effectiveness of MTII in 
reducing binge-like ethanol drinking. However, the ED30 dose of NAL moved the ED50 for 
MTII to the borderline between additive and synergistic interactions (see Fig. 4), suggesting 
the possibility that slightly higher doses of NAL (e.g., ED35 or ED40) may also be effective 
in synergistically augmenting the effectiveness of MTII to reduce binge-like ethanol 
drinking. 4) Isobolographic analysis of the drug interactions confirmed that the 0.26 mg/kg 
dose of MTII synergistically augmented the ability of NAL to reduce binge-like ethanol 
drinking.
These data show that a low (ED20), but not moderate (ED30), dose of MTII increased the 
effectiveness of NAL in reducing excessive ethanol intake. This somewhat surprising 
observation is likely related to the binding properties of MTII to the different MCRs, and the 
different ways in which the MC3R versus the MC4R influence ethanol drinking. We have 
previously shown that MTII fails to reduce ethanol drinking in MC4R knockout mice 
(Navarro et al., 2011), and that a MC4R-selective agonist blunts ethanol drinking (Navarro 
et al., 2005), indicating that stimulation of MC4R signaling is protective against excessive 
ethanol intake. More recently, we found that MTII was more effective in blunting binge-like 
ethanol drinking in mutant mice lacking the MC3R (Olney et al., 2014), indicating that 
stimulation of the MC3R counteracts against the protective effects of MTII. While often 
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considered to be a non-selective agonist, MTII has 5-fold to 7-fold higher affinity for the 
MC4R relative to the MC3R (Bednarek et al., 1999, Schioth et al., 1997). Thus, when given 
in lower subthreshold doses (e.g., the 0.26 mg/kg), MTII would be expected to have greater 
activity at the MC4R relative to the MC3R. At moderate subthreshold doses (e.g., the 0.52 
mg/kg dose), MTII would be expected to be more likely to activate both the MC3R and 
MC4R. We speculate that the low dose of MTII synergistically augmented NAL-induced 
reductions of binge-like ethanol drinking through primary actions on the MC4R, but that the 
higher dose of MTII failed to alter the effectiveness of NAL because stimulation of the 
MC3R counteracted the beneficial effects of MC4R activity. While the mechanism 
underlying the interaction between MC3R and MC4R signaling is not clear, MC3Rs exert 
inhibitory control over neurons (Cowley et al., 2001), while MC4Rs can either excite or 
inhibit neurons depending on brain location (Kawashima et al., 2003). One possibility is that 
MC3Rs inhibit post-receptor excitation caused by MC4R activation on neurons that these 
receptors are co-expressed. On the other hand, when given at high enough doses, MTII alone 
reduces ethanol drinking (see Figure 1), suggesting that doses of MTII that clear threshold 
levels can overcome, at least in part, the opposing actions of MC3R activation on the 
MC4R.
We have previously shown the administration of MTII to mice does not alter blood ethanol 
levels (Navarro et al., 2003), suggesting that activation of MCRs does not alter the 
absorption of ethanol into the bloodstream or change the rate of ethanol metabolism and 
elimination. It has also been shown that NAL over a dose range of 1.5 to 4.5 mg/kg 
produced a small but significant reduction of ethanol absorption into the bloodstream of rats, 
an effect that was not dose-related. The authors concluded that the very modest and non-
dose-dependent effect of NAL on BECs were not a sufficient condition to induce changes in 
ethanol intake (Linseman and Le, 1997). Further, reduced BECs would be expected to 
increase ethanol intake, yet NAL blunts ethanol drinking. Taken together, the effects of 
NAL and MTII on binge-like ethanol drinking, and the synergistic interaction between these 
drugs, are unlikely related to pharmacokinetics factors. We have also shown that MTII, in 
addition to reducing ethanol drinking, attenuates food intake, and sucrose (caloric) and 
saccharin (non-caloric) drinking, without influencing water intake (Navarro et al., 2011). 
Similarly, in addition to blunting binge-like ethanol drinking (Kamdar et al., 2007), NAL 
has been shown to reduce food (Tannenbaum and Pivorun, 1984) and saccharin (Yirmiya et 
al., 1988) intake in mice. Together, these observations suggest that MCR agonists and opioid 
antagonists reduce the consumption of salient reinforcers regardless of caloric content, and 
though not tested these observations would suggest that combined administration of MTII 
and NAL would also blunt consumption of a range of salient reinforcers. While the 
neurobiological mechanisms underlying the synergistic interaction between NAL and MTII 
are at present unknown, one interesting possibility involves interactions between the opioid 
and MC systems within the hypothalamus, as opioid receptors negatively regulate MC-
producing neurons in this brain region (Ibrahim et al., 2003, Loose and Kelly, 1990, Kelly et 
al., 1990). Additionally, the opposing effects of NAL and MTII on G protein-coupled 
receptor signaling, as discussed in the introduction (Alvaro et al., 1997, Contreras and 
Takemori, 1984), represents another potential mechanism of synergistic interaction between 
these systems.
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A large body of pre-clinical and clinical evidence demonstrate that NAL reduces ethanol 
drinking in humans, yet NAL based therapies are not successful with all individuals 
(Garbutt, 2009), and recent data suggest that NAL produces only modest reductions of 
ethanol drinking relative to placebo controls (Del Re et al., 2013). Thus, approaches that 
increase the effectiveness of NAL in managing excessive ethanol drinking would have high 
clinical value. We have shown that agonists of MCRs reduce excessive binge-like drinking 
in animal models, and we report here that the MCR agonist MTII synergistically augments 
the ability of NAL to blunt excessive ethanol drinking. These pre-clinical observations 
suggest that a) pharmaceutical compounds that stimulate MC signaling may be effective in 
reducing frequent binge drinking and heavy alcohol use in humans and b), that combining 
drugs that stimulate MC signaling with NAL may increase the overall effectiveness of NAL-
based therapies for treating alcohol abuse disorders. However, it should be emphasized that 
the present study is only the first work suggesting a synergistic interaction between opioids 
and MC system in modulating of ethanol consumption. Additional proof-of-concept pre-
clinical studies are clearly necessary before clinical applications are justifiable. Once 
sufficient pre-clinical data are gathered, and as safe MCR agonists become available, 
assessment of the effectiveness of these compounds, alone and in combination with NAL, in 
curbing alcohol abuse disorders should be considered. In fact, MK-0493, an orally 
bioavailable MC4R agonist, was recently tested in human phase I/II clinical trial studies for 
obesity treatment (Krishna et al., 2009) and may be effective in treating alcohol abuse 
disorders. Interestingly, as our studies employed an animal model of non-dependent binge 
drinking (Rhodes et al., 2005, Thiele and Navarro, 2014), our results specifically speak to 
the possibility that these targets could be useful for curbing excessive binge drinking, an 
approach that may be useful for preventing the transition to dependence. Such an approach 
has been argued as having the potential of being a more effective therapeutic strategy than 
treating ethanol dependence that has already emerged (Thiele, 2012, Thiele and Navarro, 
2014). Future studies employing appropriate models will be necessary to determine if MC 
agonists, alone and in combination with NAL, represents an effective approach for curing 
dependence-induced excessive ethanol drinking.
In conclusion, here we provide evidence that a MCR agonist synergistically augments that 
ability of NAL to blunt excessive ethanol intake in a mouse model of binge ethanol 
drinking. While NAL-based therapies are effective in reducing abusive ethanol drinking, this 
approach is not effective in all individuals (Garbutt, 2009). The current observations suggest 
that activators of MC signaling may represent a new approach to treating alcohol abuse 
disorders, and a way to potentially improve existing NAL-based therapies. Interestingly, the 
drug Contrave, which combines NAL and bupropion (a drug which has been reported to 
increase MC signaling (Hasegawa et al., 2005, Billes and Cowley, 2007)) into one 
medication, has recently been approved by US Food and Drug Administration (FDA) for 
treating eating disorders (Gohil, 2014); repurposing this drug to treat alcohol abuse disorders 
represents an exciting possibility.
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Intraperitoneal (i.p.) injection of naltrexone (NAL) or melanotan-II (MTII) blunt binge-like 
ethanol drinking (A & C) and associated blood ethanol concentrations (B & D) in C57BL/6J 
mice when administered over a range of concentrations (0, 0.3, 1.0, 3.0, & 10.0 mg/kg). 
Ethanol consumption is expressed as mean intake (± SEM) over the 2-h test in g/kg, and 
BECs are expressed as mean (± SEM) mg/dl of ethanol in blood. Data were analyzed with 
one-way ANOVAs and post hoc Tukey’s test. * P < 0.05 (two tailed).
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The effect of NAL alone, and in combination with the ED20 (0.26 mg/kg) and ED30 (0.52 
mg/kg) doses of MTII, on binge-like ethanol intake. When administered in combination with 
selected doses of NAL (0.3 to 3.0 mg/kg), the ED20 dose of MTII produced leftward shifts 
in the NAL dose-effect curve. Based on the ED50 values, the 0.26 mg/kg dose of MTII 
shifted the NAL dose-effect curve (ED50 of 1.07 mg/kg, 0.50 – 2.27 C.L.) to the left by a 
factor of 7.6; that is, naltrexone was 7.6-fold more potent when administered in combination 
with MTII relative to when it was administered alone. On the other hand, the ED30 dose of 
MTII slightly decreased the effects of all doses of NAL to a similar extent. Ethanol 
consumption data are expressed as percent ethanol consumption (± SEM) on test day (day 4) 
relative to baseline ethanol consumption averaged over days 1–3 of the DID procedure. Data 
were analyzed with a two-way, 3 × 3 (NAL dose x MTII dose) ANOVA and post hoc 
Tukey’s test. Post hoc comparisons of the significant drug combination main effect revealed 
that combining the 0.26 mg/kg (ED20) dose of MTII with NAL increased the ability of NAL 
to blunt binge-like ethanol drinking relative to the NAL alone condition.
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The effects of MTII alone, and in combination with the approximate ED20 (0.82 mg/kg) and 
ED30 (1.64 mg/kg) doses of NAL, on binge-like ethanol drinking. Neither ED20 nor ED30 
doses of MTII had substantial influence on the NAL dose-effect curve. Ethanol consumption 
data are expressed as percent ethanol consumption (± SEM) on test day (day 4) relative to 
baseline ethanol consumption (averaged intake over days 1–3 of the DID procedure). Data 
were analyzed with a two-way, 3 × 3 (MTII dose x NAL dose) ANOVA and post hoc 
Tukey’s test. Post hoc comparisons of the significant MTII dose-response factor revealed 
that each of the MTII doses differed from each other, reflecting the dose-dependent blunting 
of binge-like ethanol drinking by MTII.
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Isobolographic analysis of the effects of NAL and MTII administered in selected 
combinations. For this analysis, the ED50 and 95% confidence levels (C.L.) for the effects of 
NAL (solid circle) and MTII (solid square) alone on binge-like ethanol drinking were 
plotted along the abscissa and ordinate, respectively. Then the ED50 and 95% C.L. for drugs 
when tested in combination with the ED20 or ED30 of the other drug were plotted. The area 
between dashed lines that connect the 95% C.L. of the ED50 for each drug alone represents 
the “area of additivity”, the area in which drug interactions were considered to be additive. 
The region to the left of the dashed line defines synergistic drug interactions. The data show 
that the low ED20 dose of MTII (0.26 mg/kg) synergistically augmented the ability of NAL 
to blunt binge-like ethanol drinking, shifting the dose-response ED50 value of NAL to the 
left beyond the area of additivity and into the region representing synergistic drug 
interactions. Neither the low ED20 (0.82 mg/kg) nor high ED30 (1.64 mg/kg) doses of NAL 
synergistically altered the ED50 values for MTII-induced blunting of binge-like ethanol 
drinking, as the ED50 for these drug dose combinations fell within the area of additivity.
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